Cipla, a leading drug maker in India, has acquired additional 75% stake in Mabpharm through its wholly owned subsidiary Meditab Specialities.

The company was earlier holding 25% stake in Mabpharm.

Consequent to the acquisition of the aforesaid stake, Mabpharm has now become 100% subsidiary of the company.

Mabpharm is inter alia engaged in development of monoclonal anitbodies for treatment of cancer and auto-immune diseases.

Shares of the company gained Rs 5.35, or 1.24%, to settle at Rs 437.15. The total volume of shares traded was 101,716 at the BSE (Thursday).